A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Abstract Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the blood-brain barrier after...

Full description

Bibliographic Details
Main Authors: Eurydice Angeli, Justine Paris, Olivier Le Tilly, Céline Desvignes, Guillaume Gapihan, Didier Boquet, Frédéric Pamoukdjian, Diaddin Hamdan, Marthe Rigal, Florence Poirier, Didier Lutomski, Feriel Azibani, Alexandre Mebazaa, Amaury Herbet, Aloïse Mabondzo, Géraldine Falgarone, Anne Janin, Gilles Paintaud, Guilhem Bousquet
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Experimental Hematology & Oncology
Subjects:
HER2 breast cancer
Brain metastases
Fab
Trastuzumab
Pharmacokinetic
Online Access:https://doi.org/10.1186/s40164-024-00513-7

Internet

https://doi.org/10.1186/s40164-024-00513-7

Similar Items